Mymd Pharmaceuticals Inc (MYMD)

$2.35

+0.16

(+7.31%)

Market is closed - opens 7 PM, 20 May 2024

Insights on Mymd Pharmaceuticals Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 59.2% return, outperforming this stock by 155.6%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 230.2% return, outperforming this stock by 328.1%

Performance

  • $2.20
    $2.36
    $2.35
    downward going graph

    6.38%

    Downside

    Day's Volatility :6.9%

    Upside

    0.55%

    downward going graph
  • $2.00
    $70.50
    $2.35
    downward going graph

    14.89%

    Downside

    52 Weeks Volatility :97.16%

    Upside

    96.67%

    downward going graph

Returns

PeriodMymd Pharmaceuticals IncIndex (Russel 2000)
3 Months
-41.44%
0.0%
6 Months
-74.83%
0.0%
1 Year
-96.4%
-0.3%
3 Years
-97.91%
-20.6%

Highlights

Market Capitalization
4.7M
Book Value
$6.06
Earnings Per Share (EPS)
-5.33
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-57.77%
Return On Equity TTM
-29.12%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-28.2M
Diluted Eps TTM
-5.33
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Mymd Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Technicals Summary

Sell

Neutral

Buy

Mymd Pharmaceuticals Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Mymd Pharmaceuticals Inc
Mymd Pharmaceuticals Inc
-2.67%
-74.83%
-96.4%
-97.91%
-98.37%
Moderna, Inc.
Moderna, Inc.
28.27%
73.57%
5.66%
-17.3%
474.87%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
7.41%
20.63%
29.13%
84.82%
217.43%
Novo Nordisk A/s
Novo Nordisk A/s
6.83%
31.22%
59.23%
230.21%
468.67%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
12.09%
25.72%
29.14%
103.67%
161.15%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Mymd Pharmaceuticals Inc
Mymd Pharmaceuticals Inc
NA
NA
NA
0.0
-0.29
-0.58
NA
6.06
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.04
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
28.9
28.9
1.46
44.2
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
46.14
46.14
2.36
3.46
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.41
28.41
0.53
17.11
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Mymd Pharmaceuticals Inc
Mymd Pharmaceuticals Inc
Buy
$4.7M
-98.37%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$49.5B
474.87%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$107.8B
217.43%
28.9
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$589.9B
468.67%
46.14
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$112.9B
161.15%
28.41
39.46%

Institutional Holdings

  • Mirae Asset Global Investments (Korea) Co Ltd

    4.80%
  • Vanguard Group Inc

    2.25%
  • Geode Capital Management, LLC

    0.45%
  • BlackRock Inc

    0.32%
  • Praetorian Wealth Management Inc

    0.31%
  • State Street Corporation

    0.19%

Company Information

mymd is a clinical stage biotech pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms. mymd-1 is a drug platform based on a clinical stage small molecule that regulates the immunometabolic system to control tumor necrosis factor alpha (tnf-α) and other pro-inflammatory cytokines. mymd-1 is being developed to treat autoimmune diseases, including those currently treated with non-selective tnf-α blocking drugs, and aging and longevity. supera-cbd is a drug platform based on a novel (patent pending) synthetic derivative of cannabidiol (cbd) that targets numerous key receptors including cb2 and opioid receptors and inhibits monoamine oxidase. supera-cbd is being developed to address the rapidly growing cbd market that includes fda approved drugs and cbd products not currently regulated as a drug.

Organization
Mymd Pharmaceuticals Inc
Employees
6
CEO
Dr. Christopher C. Chapman Jr., M.D.
Industry
Miscellaneous

FAQs